Ghada N Farhat1, Neeta Parimi, Rowan T Chlebowski, Joann E Manson, Garnet Anderson, Alison J Huang, Eric Vittinghoff, Jennifer S Lee, Andrea Z Lacroix, Jane A Cauley, Rebecca Jackson, Deborah Grady, Dorothy S Lane, Lawrence Phillips, Michael S Simon, Steven R Cummings. 1. Affiliations of authors: San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA (GNF, NP, SRC); Faculty of Health Sciences, University of Balamand, Beirut, Lebanon (GNF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC); Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (JEM); Fred Hutchinson Cancer Research Center, Seattle, WA (GA, AZL); Department of Internal Medicine, University of California-San Francisco, San Francisco, CA (AH, DG); Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA (EV); Department of Internal Medicine, University of California-Davis, Sacramento, CA (JSL); Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (JAC); Department of Internal Medicine, Ohio State University, Columbus, OH (RJ); Department of Preventive Medicine, Stony Brook University, Stony Brook, NY (DL); Department of Medicine, Emory University, Atlanta, GA (LP); Karmanos Cancer Institute, Wayne State University, Detroit, MI (MSS).
Abstract
BACKGROUND: Although high endogenous sex hormone levels and estrogen plus progestin (E+P) therapy are associated with increased breast cancer risk, it is unknown whether pretreatment levels of sex hormones modify E+P effect on breast cancer. METHODS: We conducted a nested case-control study within the Women's Health Initiative randomized clinical trial of E+P. The trial enrolled 16608 postmenopausal women aged 50 to 79 years with intact uterus and no breast cancer history. During a mean of 5.6 years of follow-up, 348 incident breast cancer case subjects were identified and matched with 348 control subjects. Case and control subjects had their sex hormone levels measured at baseline (estrogens, testosterone, progesterone, and sex hormone-binding globulin [SHBG]) and year 1 (estrogens and SHBG) using sensitive assays. All statistical tests were two-sided. RESULTS: Statistically significant elevations in breast cancer risk were seen with greater pretreatment levels of total estradiol (P trend = .04), bioavailable estradiol (P trend = .03), estrone (P trend = .007), and estrone sulfate (P trend = .007). E+P increased all measured estrogens and SHGB at year 1 (all P < .001). The effect of E+P on breast cancer risk was strongest in women whose pretreatment levels of total estradiol, bioavailable estradiol, and estrone were in the lowest quartiles. For example, the odds ratio for E+P relative to placebo was 2.47 (95% confidence interval [CI] = 1.28 to 4.79) in the lowest total estradiol quartile, compared with 0.96 (95% CI = 0.44 to 2.09) in the highest total estradiol quartile; P interaction = .04). CONCLUSIONS: Women with lower pr-treatment endogenous estrogen levels were at greater risk of breast cancer during E+P therapy compared with those with higher levels. Further studies are warranted to confirm these findings.
RCT Entities:
BACKGROUND: Although high endogenous sex hormone levels and estrogen plus progestin (E+P) therapy are associated with increased breast cancer risk, it is unknown whether pretreatment levels of sex hormones modify E+P effect on breast cancer. METHODS: We conducted a nested case-control study within the Women's Health Initiative randomized clinical trial of E+P. The trial enrolled 16608 postmenopausal women aged 50 to 79 years with intact uterus and no breast cancer history. During a mean of 5.6 years of follow-up, 348 incident breast cancer case subjects were identified and matched with 348 control subjects. Case and control subjects had their sex hormone levels measured at baseline (estrogens, testosterone, progesterone, and sex hormone-binding globulin [SHBG]) and year 1 (estrogens and SHBG) using sensitive assays. All statistical tests were two-sided. RESULTS: Statistically significant elevations in breast cancer risk were seen with greater pretreatment levels of total estradiol (P trend = .04), bioavailable estradiol (P trend = .03), estrone (P trend = .007), and estrone sulfate (P trend = .007). E+P increased all measured estrogens and SHGB at year 1 (all P < .001). The effect of E+P on breast cancer risk was strongest in women whose pretreatment levels of total estradiol, bioavailable estradiol, and estrone were in the lowest quartiles. For example, the odds ratio for E+P relative to placebo was 2.47 (95% confidence interval [CI] = 1.28 to 4.79) in the lowest total estradiol quartile, compared with 0.96 (95% CI = 0.44 to 2.09) in the highest total estradiol quartile; P interaction = .04). CONCLUSIONS:Women with lower pr-treatment endogenous estrogen levels were at greater risk of breast cancer during E+P therapy compared with those with higher levels. Further studies are warranted to confirm these findings.
Authors: Jennifer Hays; Julie R Hunt; F Allan Hubbell; Garnet L Anderson; Marian Limacher; Catherine Allen; Jacques E Rossouw Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678
Authors: Sabina Rinaldi; Annabelle Geay; Henri Déchaud; Carine Biessy; Anne Zeleniuch-Jacquotte; Arslan Akhmedkhanov; Roy E Shore; Elio Riboli; Paolo Toniolo; Rudolf Kaaks Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: Steven R Cummings; Tu Duong; Emily Kenyon; Jane A Cauley; Malcolm Whitehead; Kathryn A Krueger Journal: JAMA Date: 2002-01-09 Impact factor: 56.272
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Diego Munoz; Aimee M Near; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Oguzhan Alagoz; Donald A Berry; Elizabeth S Burnside; Yaojen Chang; Gary Chisholm; Harry J de Koning; Mehmet Ali Ergun; Eveline A M Heijnsdijk; Hui Huang; Natasha K Stout; Brian L Sprague; Amy Trentham-Dietz; Jeanne S Mandelblatt; Sylvia K Plevritis Journal: J Natl Cancer Inst Date: 2014-09-24 Impact factor: 13.506
Authors: Shanshan Zhao; Rowan T Chlebowski; Garnet L Anderson; Lewis H Kuller; JoAnn E Manson; Margery Gass; Ruth Patterson; Thomas E Rohan; Dorothy S Lane; Shirley Aa Beresford; Sayeh Lavasani; Jacques E Rossouw; Ross L Prentice Journal: Breast Cancer Res Date: 2014-03-26 Impact factor: 6.466
Authors: Neil M Iyengar; Rhonda Arthur; JoAnn E Manson; Rowan T Chlebowski; Candyce H Kroenke; Lindsay Peterson; Ting-Yuan D Cheng; Elizabeth C Feliciano; Dorothy Lane; Juhua Luo; Rami Nassir; Kathy Pan; Sylvia Wassertheil-Smoller; Victor Kamensky; Thomas E Rohan; Andrew J Dannenberg Journal: JAMA Oncol Date: 2019-02-01 Impact factor: 31.777
Authors: Ann E Drummond; Christopher T V Swain; Kristy A Brown; Suzanne C Dixon-Suen; Leonessa Boing; Eline H van Roekel; Melissa M Moore; Tom R Gaunt; Roger L Milne; Dallas R English; Richard M Martin; Sarah J Lewis; Brigid M Lynch Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-10-20 Impact factor: 4.254